SOUTH SAN FRANCISCO, Calif., Feb. 20, 2019 /PRNewswire/ -- GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced the publication of a study showing how it adapted its Surge™ antibody discovery and engineering platform to improve selection of OX40 agonists. The study has been published online in the peer-reviewed scientific journal, Antibodies, as part of the special issue Antibody Repertoire Mining for Immune Profiling, Antibody Discovery and Vaccine Design.
The paper, "Preferential Identification of Agonistic OX40 Antibodies by Using Cell Lysate to Pan Natively Paired, Humanized Mouse-Derived Yeast Surface Display Libraries," demonstrates that combining Surge technology with cell lysate selection methods yielded OX40 antibodies with higher therapeutic potential. Specifically, the study preferentially yielded antibodies that bound the essential epitopes for antibody-mediated OX40 agonism. Surge, a novel method using deep sequencing, microfluidics, and yeast display to screen entire antibody repertoires, was used to evaluate two methods of immunizing Trianni mice and two selection methods to improve the discovery process of therapeutic monoclonal antibodies.
"Our mission is to use the best possible techniques to achieve unparalleled insight into the immune system, and in this case, we have found the ideal approach to generating antibodies against cell surface targets that are difficult to express in a soluble format," said David Johnson, chief executive officer of GigaGen. "Our Surge technology is helping us understand that depending on the target, certain assays are more effective, such as cell lysate in the case of OX40. We will continue to apply Surge to fit the needs of pursuing best-in-class therapeutic antibodies against some of the most exciting targets in oncology."
GigaGen is a privately-held, preclinical biopharmaceutical company developing novel antibody therapies to treat diseases of immune dysregulation. GigaGen's deep understanding of immune dysregulation is enabled by industry-leading technology that quickly captures the genetic makeup of entire immune repertoires to analyze B cells at a rate of millions per hour, while simultaneously identifying their antigen and protein binders. GigaGen has a robust internal pipeline consisting of novel antibodies against immuno-oncology targets, in addition to the first recombinant intravenous immunoglobulin (IVIG) for patients with immune deficiency. For more information visit www.GigaGen.com.
SOURCE GigaGen Inc.